Jonathan Alan Quine, J.D.,Ph.D., is the president and managing director of the Quine Intellectual Property Law group, P.C. Since the inception of the firm in 1999, Dr. Quine has built the firm from the solo practitioner stage into a well recognized biotechnology boutique firm, with more than 15 full time employees.

Dr. Quine's practice is split almost evenly between industrial and institutional clients. With respect to industrial clients, Dr. Quine has made significant contributions to the development and architecture of patent portfolios that dominate their respective industries. These industries include molecular evolution, where Dr. Quine prosecuted over 35 patents to issuance for Maxygen Technologies, Inc.; and microfluidics, where Dr. Quine prosecuted over 40 patents to issuance for Caliper Technologies Corp. The Maxygen patent portfolio was ranked as the top (#1) rated patent portfolio in biotechnology by the M.I.T. Technology Review's 2003 Patent Scorecard. The Caliper Technologies Corp. patent portfolio was also one of the top rated patent portfolios in biotechnology, as ranked by the M.I.T. Technology Review's 2002 and 2003 Patent Scorecards (holding a #2 ranking in 2003). Dr. Quine's institutional clients include the University of California (most campuses), Stanford University, The Scripps Research Institute, The Salk Research Institute, The University of Pennsylvania, and the University of Colorado, where Dr. Quine has been an invited guest lecturer on topics ranging from institutional-industrial partnering opportunities, to the patenting of crystallographic inventions.

Dr. Quine has significant expertise in a variety of technical fields, including molecular and cellular biology, pharmacology, genetics, RNAi, microfluidic and other cutting edge laboratory technologies, nano technology, laboratory instrumentation, rapid molecular evolution, orthogonal translation systems for the in vivo incorporation of unnatural amino acids into proteins, agricultural technology, immunology, vaccine development, gene therapy, bioinformatics, and mechanical devices.

Dr. Quine has extensive experience in client counseling and patent portfolio management, as well as in patent preparation and prosecution, opinion drafting, due diligence matters, interference practice and litigation support. Dr. Quine has counseled early, mid and mature stage clients in how best to acquire, develop, manage, maintain and use their intellectual property to maximum business advantage, world-wide. Dr. Quine has assisted companies with their intellectual property matters during their successful transitions from privately to publicly held companies. Dr. Quine has extensive prosecution expertise, having successfully prosecuted hundreds of cases to issuance. This experience includes over 100 in person interviews at the United States Patent Office (a rarity for a west coast practitioner) and the take-over and prosecution of many difficult "problem" cases for a variety of clients. Dr. Quine's opinion practice is extensive and theories laid out in his opinions have been successfully tested in critical infringement/validity patent litigation.

Prior to founding the Quine Intellectual Property Law Group, P.C., in March of 1999 (then named "The Law Offices of Jonathan Alan Quine"), Dr. Quine practiced as an attorney at Townsend and Townsend and Crew, LLP. Dr. Quine has a J.D. degree from The University of California at Berkeley, a Ph.D. in Molecular Biology from Vanderbilt University and a B.S. in Biological Science from The University of Denver (magna cum laude, Phi Beta Kappa). Dr. Quine is registered to practice before the U.S. Patent and Trademark Office and is registered to practice as an attorney in the state of California.

Stephen J. LeBlanc, J.D., joined the Quine Intellectual Property Law Group, P.C., as Of Counsel in November 2000. Prior to joining the firm, he practiced as an associate attorney at Townsend and Townsend and Crew, LLP, and at Majestic, Parsons, Siebert and Hsue, LLP. Mr. LeBlanc specializes in patent drafting and prosecution, strategic patent planning, and client counseling. He has extensive engineering and patent experience in digital electronics, information processing, database design, computer and microprocessor architecture, and advanced digital communication technologies. He has drafted patents in a range of specific technology areas, including Ethernet, SONET, ATM, TCP/IP, wireless modems, streaming media, XML, RTSP, SMIL, 3D scanning, speech recognition, database analysis and data-mining, network security and deception systems, bioinformatics and data compression technologies. Mr. LeBlanc holds a J.D. from Northeastern University School of Law in Boston, Massachusetts, where he received a Dean's Scholarship, and holds a Bachelor of Science degree in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology. Mr. LeBlanc was admitted to practice before the U.S. Patent and Trademark Office in 1992 and is registered to practice as an attorney in California.

Gary L. Baker, M.T., J.D. joined the Quine Intellectual Property Law Group, P.C., in November of 2001. Mr. Baker had a small private legal practice in intellectual property and civil law prior to joining the firm. He has 18 years of industrial experience, mostly at Chiron Corporation, in molecular biology, cell biology, instrumentation, analysis and purification processes. Before the biotech bug bit him, Mr. Baker was also a registered Clinical Laboratory Scientist at Stanford Medical Center. He received his J.D. from the University of San Francisco School of Law. His medical technology internship was at Long Beach Memorial Medical Center and he briefly studied genetics at San Francisco State University. Mr. Baker received his B.S. in microbiology from Montana State University. Mr. Baker is registered to practice before the United States Patent and Trademark Office and is admitted to practice as an attorney in the State of California.

Stacy M. Landry, J.D., Ph.D. returned to the Quine Intellectual Property Law Group, P.C., in November 2006. Her practice emphasizes biotechnology patent prosecution. She has a B.S. degree in Chemistry from Louisiana State University at Baton Rouge Louisiana (1989). She received her Ph.D. in Biophysical Chemistry from the University of California at Berkeley in 1995 and her J.D. from the University of California Hastings College of the Law (cum laude) in 1998. Upon graduation from law school Stacy worked as an associate attorney at Townsend and Townsend and Crew in San Francisco and joined the Quine Intellectual Property Law Group shortly after its formation in 1999. During her absence from the Quine group, Stacy gave birth to a daughter and worked as in-house patent counsel for PDL-Biopharma. She is registered to practice before the United States Patent and Trademark Office and is admitted to practice as an attorney in the State of California.

Paul B. Littlepage, J.D., M.S., joined the Quine Intellectual Property Law Group, P.C., in July 2000. His practice emphasizes biotechnology patent prosecution. His undergraduate degrees are in Microbiology and Physiology both from Southern Illinois University at Carbondale (magna cum laude, 1990). He received his M.S. in Microbiology from the University of California at Davis in 1992 and his J.D. from the University of California at Davis (Order of the Coif) in 1997. He has worked at the Center for Population Biology at the University of California at Davis and at The Sapiro Law Firm in San Francisco. He is registered to practice as an attorney in the state of California.

Monicia Elrod-Erickson, Ph.D., joined the Quine Intellectual Property Law Group, P.C., in April, 2002. She received her Ph.D. in Biology from the Massachusetts Institute of Technology (1998) and has postdoctoral training from the Whitehead Institute for Biomedical Research. Dr. Elrod-Erickson has a B.S. with high honors in Molecular Biology from Vanderbilt University (summa cum laude, 1991) and has worked as a scientific curator for Incyte Genomics, Inc. Her research experience includes genetic analysis of innate immunity in Drosophila and x-ray crystallographic and biochemical analysis of DNA-binding proteins. She is registered as a patent agent to practice before the U.S. Patent and Trademark Office.

Brian E. Davy, Ph.D., joined the Quine Intellectual Property Law Group, P.C., in May 2008. He received his Ph.D. in Molecular, Cellular and Developmental Biology from Ohio State University in June 2004. As a graduate student, Dr. Davy identified and characterized a novel gene in mice (Hydin) which . when mutated . results in congenital hydrocephalus. After receiving his Ph.D., Dr. Davy was awarded an NIH post doctoral fellowship to conduct research in the Department of Genome Sciences at Lawrence Berkeley National Laboratory (LBNL). At LBNL, he elucidated the murine neural expression pattern of SatB1, a gene required for the establishment of higher order chromatin structure in mammalian nuclei. After conducting post doctoral research for two years, Dr. Davy entered law school at Santa Clara University in August 2006. After his first year in law school, he worked as a summer patent intern at Affymetrix, Inc. (Santa Clara, CA), where he assisted in the prosecution of patent applications directed to large-scale oligonucleotide arrays for the analysis of gene expression and genome mapping. Dr. Davy expects to receive his J.D. in May 2009, and is currently registered to practice as a patent agent before the United States Patent and Trademark Office.

Angela P. Horne, Ph.D., joined the Quine Intellectual Property Law Group, P.C., in February 2000. Prior to joining Quinelaw, Dr. Horne held the position of Patent Agent at Cygnus, Inc. (Redwood City, CA), where she assisted in the prosecution of patent applications in the areas of transdermal drug delivery and glucose monitoring. During her two-year stint at Cygnus Inc., she was recognized twice by the company with awards for "Entrepreneurial Spirit."

Prior to becoming a patent agent, Dr. Horne worked as a research scientist in the fields of biotechnology and drug discovery. During her years of employment with Glycomed, Inc. (Alameda, CA) and Ligand Pharmaceuticals (San Diego, CA), her research was directed to the areas of NMR spectroscopy, carbohydrate chemistry, and inflammation. In addition to research into the interactions between inflammatory cascade proteins and carbohydrate-based drug leads, Dr. Horne maintained the two on-site NMR spectrometers, participated in various R&D and clinical trial committees, and coordinated and maintained the Glycomed compound library of proprietary drug leads generated by the prolific chemistry department. During her last couple of years at Glycomed, Inc., she was also responsible for managing the NMR and molecular modeling facility.

Dr. Horne has a Ph.D. in Biochemistry from Vanderbilt University (1992), where her research focused on the interactions between heparin and the blood protein antithrombin, and a Bachelors of Science with High Honors in Microbiology and Cell Sciences from the University of Florida (1985). Dr. Horne is registered as a patent agent to practice before the U.S. Patent and Trademark Office.

Edward DesJardins, Ph.D. , currently on sabbatical, joined the Quine Intellectual Property Law Group, P.C., in December 2003. Prior to joining the firm, Dr. DesJardins was a Patent Agent at Knobbe Martens Olson & Bear, LLP in San Francisco. Dr. DesJardins specializes in patent preparation, prosecution and analysis in the biotechnology arts. Dr. DesJardins was previously a postdoctoral fellow at the University of Colorado at Boulder in the Department of Molecular, Cellular and Developmental Biology, where he was a funded fellow of the Department of Defense Breast Cancer Research Program. Dr. DesJardins holds a Ph.D. from the University of Chicago (1996) in the Department of Molecular Genetics and Cell Biology, where he was recognized for his research and received a Bristol-Meyers Oncology Division Young Investigator Award at the 1994 American Association of Cancer Research Annual Meeting. Dr. DesJardins received his A.B. in Biochemistry from Bowdoin College (1986) and has experience as a Research Technician in the Department of Molecular Biology at Massachusetts General Hospital in Boston. He is registered to practice as a patent agent before the U.S. Patent and Trademark Office.

Christina Onufryk, Ph.D. joined the Quine Intellectual Property Law Group, P. C., in July, 2007. She received her Ph.D. in Biochemistry from the University of California, San Francisco, where she was a Howard Hughes Predoctoral Fellow from 1996 - 2001. Her research at UCSF focused on the role of σ^E -transcribed lipoproteins in maintaining the barrier function of the outer membrane in E. coli. Dr. Onufryk earned a B.S. in Biology from the Massachusetts Institute of Technology, and she was elected to MIT.s chapter of Phi Beta Kappa in 1995. She is a registered before the U. S. Patent and Trademark Office.